"
Others-
Reboxetine?????????????????????????????????????????????????????????????????????????????????
Others
相关产品
SBE-β-CD-MPTP hydrochloride-Cyclosporin A-Etomoxir-Auranofin-GKT137831-Ceruletide-Acetylcysteine-JC-1-BPTES-Brassinolide-FCCP-IPTG-MTT-RSL3 1S,3R--
生物活性
Description
Reboxetine Mesylate is a norepinephrine reuptake inhibitor use in the treatment of unipolar depression.Target: OthersReboxetine is a drug of the norepinephrine reuptake inhibitor class. Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 ??g/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the ??2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively [1]. Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution [2]. Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex [3].
Clinical Trial
NCT00372190
Radboud University
Pelvic Organ Prolapse
August 2006
NCT00572702
Charles University, Czech Republic-Ministry of Health, Czech Republic
Pelvic Organ Prolapse
January 2007
NCT00833001
Ethicon, Inc.
Cystocele-Rectocele-Enterocele
April 2008
Phase 2-Phase 3
NCT03070873
Nanjing Medical University
Pelvic Organ Prolapse
January 1, 2010
NCT02231099
Radboud University
Pelvic Organ Prolapse-Cystocele-Rectocele-Uterine Prolapse
January 2011
NCT00566917
Karolinska Institutet-The regional agreement on medical training and clinical research (ALF) between Stockholm county council and Karolinska Institutet.-The Swedish Society of Medicine-Investigators meetings supported by Gynecare Scandinavia.
Vaginal Prolapse
December 2007
Phase 4
NCT00679276
William Beaumont Hospitals
Vaginal Prolapse
May 2008
NCT00402844
Karolinska Institutet-Karolinska University Hospital
Pelvic Organ Prolapse
August 2006
Phase 2-Phase 3
NCT00886886
University Hospital, Basel, Switzerland
Mood Disorder-Substance-related Disorders-Amphetamine-related Disorders
April 2009
Phase 1
NCT00209807
Hospital Universitari Vall d'Hebron Research Institute
Major Depression-Pain-Abdominal Pain
September 2005
Phase 4
NCT00754221
Pfizer
Fibromyalgia
May 2008
Phase 3
NCT00426946
Geha Mental Health Center
Depression
January 2005
Phase 4
NCT00353808
Pfizer
Pain
July 2006
Phase 2
NCT00409201
Abarbanel Mental Health Center
Schizophrenia
March 2006
Phase 1
NCT00348894
Pfizer
Pain
July 2006
Phase 2
NCT00612170
Pfizer
Fibromyalgia
December 2007
Phase 3
NCT00334685
Pfizer
Pain
July 2006
Phase 2
NCT01300364
Fundació Sant Joan de Déu-Centro de Investigación Biomédica en Red de Salud Mental
Schizophrenia
November 2008
Phase 4
NCT00288652
Pfizer
Pain
March 2006
Phase 2
NCT00354094
Pfizer
Pain
November 2006
Phase 2
NCT00357825
Pfizer
Pain
August 2006
Phase 2
NCT00444548
Pfizer
Healthy
May 2007
NCT00143442
Pfizer
Pain
December 2003
Phase 2
NCT00625833
Pfizer
Diabetic Neuropathies
December 2007
Phase 2
NCT00562055
Pfizer
Attention Deficit Hyperactivity Disorder
November 2007
Phase 2
NCT00607256
Pfizer
Fibromyalgia
October 2007
Phase 3
NCT00636246
Pfizer
Depressive Disorder, Major
June 2004
Phase 2
NCT00853866
Universitätsklinikum Hamburg-Eppendorf-German Research Foundation-University Hospital Tuebingen
Cerebral Stroke
January 2009
Phase 4
NCT00421369
Hadassah Medical Organization
Major Depressive Disorder
September 2007
NCT02179268
Guiyang Medical University
Bone Mineral Density Quantitative Trait Locus 7
March 2012
Phase 3
NCT00993876
Zentrum für Integrative Psychiatrie-German Research Foundation
Cognitive Performance in Major Depression
August 2005
NCT02374567
Hannover Medical School
Dementia-Depression-Schizophrenia-Psychosomatic Disorders-Anxiety Disorders
January 2015
Phase 3
View MoreCollapse
References
[1].Wong, E.H., et al., Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry, 2000. 47(9): p. 818-29.
[2].Versiani, M., et al., Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry, 1999. 60(6): p. 400-6.
[3].Page, M.E. and I. Lucki, Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology, 2002. 27(2): p. 237-47.